Mirum Pharmaceuticals: A Pivotal Year of Clinical Catalysts and Financial Milestones

Mirum Pharmaceuticals is entering what could be its most transformative period. The rare disease specialist faces a packed calendar of clinical data readouts that will shape its long-term commercial trajectory, while its financial performance signals a decisive move toward sustained profitability.

Financial Performance Sets the Stage

Operationally, Mirum is demonstrating significant scaling. Company leadership has provided a 2026 product revenue forecast ranging from $630 million to $650 million. This projection represents a meaningful increase over the $521.3 million reported the previous year. A critical milestone for investors was reached in the third quarter of 2025, when the company posted its first-ever net profit, underscoring the scalability of its business model.

Market sentiment, however, has recently reflected a degree of investor caution. Shares closed at €77.00 on Friday, trading approximately 17% below the 52-week high set in February. The stock’s elevated volatility, measured at nearly 55%, highlights the market’s nervous anticipation of the upcoming clinical results.

The next significant update for shareholders is anticipated in late April or early May, when Mirum will disclose its first-quarter 2026 financials. This report will be closely scrutinized to determine if LIVMARLI, the flagship revenue driver which recently contributed over $90 million per quarter, continues to meet high growth expectations.

Should investors sell immediately? Or is it worth buying Mirum Pharmaceuticals?

A Sequential Wave of Clinical Data

The company’s clinical pipeline is poised for several near-term catalysts that will define its expansion potential. The Volixibat program is a primary focus, with topline data from the Phase 2b VISTAS study in primary sclerosing cholangitis (PSC) expected in the second quarter of 2026. A positive outcome here would mark a major step in broadening Mirum’s therapeutic portfolio.

Furthermore, the hepatitis delta virus program for brelovitug is advancing, with 24-week results anticipated in the second half of 2026. These data are intended to form the foundation for a potential U.S. regulatory submission.

The clinical agenda for the year is precisely scheduled:
* Q2 2026: Volixibat data from the VISTAS study in PSC.
* H2 2026: 24-week results for brelovitug in hepatitis delta.
* Q4 2026: Phase 3 data for LIVMARLI from the EXPAND study.

The convergence of these clinical milestones with the company’s accelerating revenue and path to profitability sets the stage for a potentially defining year for Mirum Pharmaceuticals.